Every material Form 8-K ESAB filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ESAB appointed Dr. Sébastien Martin, an Associate Professor of Operations at Northwestern's Kellogg School of Management, as a director effective January 1, 2026, and he will join the Audit Committee. The company also said director Patrick Allender will retire at its 2026 annual meeting of stockholders, with no disagreement with the company cited. The filing contains no financial results, so the change is administrative and governance-related for shareholders.
Dr. Sébastien Martin appointed director effective January 1, 2026; Board size increases from nine to ten members.
Dr. Martin joins the Audit Committee effective January 1, 2026, and has served as an external AI advisor to ESAB since February 2025.
Patrick Allender will retire as a director at the 2026 annual meeting of stockholders; the company says it is not due to any disagreement.
The Board determined Dr. Martin is independent under NYSE listing standards.
ESAB reported third-quarter 2025 sales of $728 million, up 8% on a reported basis and 2% on a core organic basis, and completed the EWM acquisition. Diluted EPS from continuing operations was $1.04, down from $1.13 a year earlier, while core adjusted EPS rose to $1.32 from $1.25. The company raised its full-year 2025 core sales growth and core adjusted EBITDA outlook, which matters to shareholders because it changes the company's expected full-year results.
Q3 sales $728 million, up 8% reported and 2% core organic; net income from continuing operations attributable to ESAB $64 million
Diluted EPS $1.04 versus $1.13 a year earlier; core adjusted diluted EPS $1.32 versus $1.25
2025 core sales growth outlook raised to 4.5%-5.5% from 1.5%-3.5%; core adjusted EBITDA outlook raised to $535-$540 million from $525-$535 million
Core adjusted EPS outlook narrowed to $5.20-$5.30 from $5.15-$5.30
ESAB Corporation entered into an amended and restated credit agreement with Bank of America as administrative agent. The new facilities replace its existing $400 million term loan A and $750 million revolving credit facility, and the company says proceeds will fund working capital and corporate purposes.
New $350 million senior term loan A facility and $1.05 billion senior revolving credit facility, both maturing October 16, 2030.
Proceeds repaid the existing $400 million term loan A and $750 million revolving credit facility, plus fees and related costs.
Initial margin of 1.250% for term SOFR loans, with future pricing tied to total leverage ratio.
Covenants include a maximum total leverage ratio of 3.50:1.00 and a minimum interest coverage ratio of 3.00:1.00.
ESAB reported second-quarter 2025 sales of $716 million, up 1% on a reported basis, and diluted EPS from continuing operations of $1.12, down from $1.37 a year earlier. Core adjusted EPS rose to $1.36 from $1.32, and the company raised its full-year 2025 core adjusted EBITDA and core adjusted EPS guidance. Shareholders get higher adjusted profit targets, but GAAP profit fell in the quarter.
Q2 2025 sales were $716 million, up 1% reported and down 1% on a core organic basis
Diluted EPS from continuing operations was $1.12 versus $1.37 a year earlier; core adjusted EPS was $1.36 versus $1.32
Full-year 2025 core adjusted EBITDA guidance raised to $525 to $535 million from $520 to $530 million
Full-year 2025 core adjusted EPS guidance raised to $5.15 to $5.30 from $5.10 to $5.25
At its May 8, 2025 annual meeting, ESAB stockholders approved the Amended and Restated 2022 Omnibus Incentive Plan, which the board adopted in February 2025. The amendments allow consultants to receive grants, raise the annual fair value limit for non-employee director awards, remove the per-person annual share limit, and extend the plan's term to 10 years, but the filing says the plan does not increase the number of authorized shares. Stockholders also elected four Class III directors, ratified Ernst & Young LLP for 2025, and approved executive pay on an advisory basis.
Plan approved with 49,897,562 votes for, 7,113,445 against, 651,736 abstentions and 770,549 broker non-votes.
Amendments add consultants as eligible grantees, remove the per-person annual share limit and extend the term to 10 years after the effective date.
The plan does not increase authorized shares; four Class III directors were elected, including Melissa Cummings, Shyam P. Kambeyanda, Robert S. Lutz and Rajiv Vinnakota.
ESAB reported first-quarter 2025 sales of $678 million, down 2% on a reported basis and flat on a core organic basis, while net income attributable to ESAB rose to $67.4 million, or $1.10 per diluted share, from $0.98 a year earlier. The company raised its full-year 2025 core sales growth outlook to (1.0)% to 1.5% and its core adjusted EBITDA outlook to $520 million to $530 million, and kept core adjusted EPS guidance at $5.10 to $5.25.
Q1 2025 sales were $678 million, down 2% reported and flat on a core organic basis; core adjusted EBITDA was $128 million, up 4%, with margin up 100 basis points to 19.8%
Diluted EPS was $1.10 on net income attributable to ESAB of $67.4 million; core adjusted diluted EPS was $1.25, compared with $1.20 a year earlier
Full-year 2025 core sales growth outlook raised to (1.0)% to 1.5% from (2.0)% to 0.0%; core adjusted EBITDA outlook raised to $520 million to $530 million from $515 million to $530 million
ESAB completed its acquisition of Bavaria Schweisstechnik GmbH on April 30, 2025
ESAB reported fourth quarter 2024 sales of $671 million, down 3% on a reported basis but flat on a core organic basis, and net income from continuing operations attributable to ESAB of $72 million, or $1.18 per diluted share. The company also issued full-year 2025 guidance, expecting core adjusted EBITDA of $515 million to $530 million and core adjusted EPS of $5.10 to $5.25, which shareholders can compare with 2024 core adjusted EPS of $5.06.
Q4 2024 net sales $671 million, down 3% reported; core organic growth flat
Q4 2024 diluted EPS $1.18 from continuing operations; core adjusted EPS $1.28 versus $1.13 a year earlier
Core adjusted EBITDA $129 million, up 2%; margin 20.3%, up 90 basis points
2025 guidance: core sales growth (2.0)% to 0.0%; core adjusted EBITDA $515 million to $530 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ESAB filing is on SEC EDGAR ↗. 8-K briefs of other companies →